BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Mycobacterium Tuberculosis, Cell Mediated Immune Response, Enzyme-Linked Immunospot Test

    PMA: P070006 · Decision Jul 30, 2008
    View on FDA
    Classifications
    1
    FEI Numbers
    1
    Registration Numbers
    1

    Basic Information

    Device Name
    Mycobacterium Tuberculosis, Cell Mediated Immune Response, Enzyme-Linked Immunospot Test
    Trade Name
    T SPOT-TB TEST
    PMA Number
    P070006
    Device Class
    FDA Class 3
    Product Code
    OJN
    Generic Name
    Mycobacterium tuberculosis, Cell mediated immune response, enzyme-linked immunospot test
    Medical Specialty
    Unknown
    Advisory Committee
    Microbiology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    July 30, 2008
    Date Received
    February 6, 2007
    Expedited Review
    N
    Docket Number
    08M-0477

    Advisory Committee Statement

    APPROVAL FOR THE T-SPOT-TB. THIS DEVICE IS INDICATED FOR USE AS AN IN VITRO DIAGNOSTIC TEST FOR THE DETECTION OF EFFECTOR T CELLS THAT RESPOND TO STIMULATION BY MYCOBACTERIUM TUBERCULOSIS ANTIGENS ESAT-6 AND CFP-10 BY CAPTURING INTERFERON GAMMA (IFN-¿) IN THE VICINITY OF T CELLS IN HUMAN WHOLE BLOOD COLLECTED IN SODIUM CITRATE OR SODIUM OR LITHIUM HEPARIN. IT IS INTENDED FOR USE AS AN AID IN THE DIAGNOSIS OF M. TUBERCULOSIS INFECTION. T-SPOT-TB IS AN INDIRECT TEST FOR M. TUBERCULOSIS INFECTION (INCLUDING DISEASE) AND IS INTENDED FOR USE IN CONJUNCTION WITH RISK ASSESSMENT, RADIOGRAPHY AND OTHER MEDICAL AND DIAGNOSTIC EVALUATIONS.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    OJN Mycobacterium Tuberculosis, Cell Mediated Immune Response, Enzyme-Linked Immunospot Test